Literature DB >> 2451346

Point mutations in glycoprotein gene of vesicular stomatitis virus (New Jersey serotype) selected by resistance to neutralization by epitope-specific monoclonal antibodies.

L H Luo1, Y Li, R M Snyder, R R Wagner.   

Abstract

Antigenic variants of the New Jersey serotype of vesicular stomatitis virus (VSV-NJ) were isolated and cloned by selecting virus plaques resistant to neutralization by high-titered monoclonal antibodies (MAbs) directed to glycoprotein (G) epitopes V, VI, VII, or VIII. The G proteins of each neutralization-resistant virus variant also exhibited markedly reduced antigenic reactivity with each corresponding epitope-specific MAb as determined by enzyme-linked immuno-absorbent assay and by Western blot analysis. Loss of antigenic reactivity of certain mutant G proteins to a MAb other than the one used to select the mutant virus suggested close antigenic proximity, particularly for epitopes VI and VII. The virion RNAs coding for the entire G gene of the wild-type virus and 10 MAb-induced mutants were sequenced by primer DNA extension using the dideoxy method. Each mutant G gene exhibited only a single nucleotide change, leading in each case to a single amino acid substitution, as follows: Glu210----Lys for all three mutants selected by MAb14 (epitope VII); Pro268----Thr for one mutant selected by MAb12 (epitope VI); Ser277----Lys for all three mutants selected by MAb15 (epitope VIII); and Glu364----Lys for all three mutants selected by MAb11 (epitope V). These neutralizing MAb-selected mutations are clustered in the middle third of the 517-amino acid VSV-NJ G protein, presumably resulting in conformational changes that alter recognition of one or more antigenic determinants by a specific monoclonal antibody.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2451346     DOI: 10.1016/0042-6822(88)90274-7

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

1.  Antigenic variation of the bovine ephemeral fever virus glycoprotein.

Authors:  D H Cybinski; S S Davis; H Zakrzewski
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

2.  Polymerase errors accumulating during natural evolution of the glycoprotein gene of vesicular stomatitis virus Indiana serotype isolates.

Authors:  P A Bilsel; S T Nichol
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

3.  Disulfide-bonded discontinuous epitopes on the glycoprotein of vesicular stomatitis virus (New Jersey serotype).

Authors:  P R Grigera; W Keil; R R Wagner
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

4.  Site-specific mutations in vectors that express antigenic and temperature-sensitive phenotypes of the M gene of vesicular stomatitis virus.

Authors:  Y Li; L Z Luo; R M Snyder; R R Wagner
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

5.  Characterization of intramolecular disulfide bonds and secondary modifications of the glycoprotein from viral hemorrhagic septicemia virus, a fish rhabdovirus.

Authors:  K Einer-Jensen; T N Krogh; P Roepstorff; N Lorenzen
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

6.  Evolution of bovine ephemeral fever virus in the Australian episystem.

Authors:  Lee Trinidad; Kim R Blasdell; D Albert Joubert; Steven S Davis; Lorna Melville; Peter D Kirkland; Fasséli Coulibaly; Edward C Holmes; Peter J Walker
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

Review 7.  Immunity to fish rhabdoviruses.

Authors:  Maureen K Purcell; Kerry J Laing; James R Winton
Journal:  Viruses       Date:  2012-01-18       Impact factor: 5.048

Review 8.  Neutralizing antiviral antibody responses.

Authors:  R M Zinkernagel; A LaMarre; A Ciurea; L Hunziker; A F Ochsenbein; K D McCoy; T Fehr; M F Bachmann; U Kalinke; H Hengartner
Journal:  Adv Immunol       Date:  2001       Impact factor: 3.543

9.  Identification of epitopes associated with different biological activities on the glycoprotein of vesicular stomatitis virus by use of monoclonal antibodies.

Authors:  S Nagata; Y Okamoto; T Inoue; Y Ueno; T Kurata; J Chiba
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.